Evaxion Biotech A/S (EVAX) IPO Opens Flat

Today's IPO for Evaxion Biotech A/S (NASDAQ: EVAX) opens for trading at $10 after pricing its initial public offering of 3,000,000 American Depositary Shares (“ADSs”), at a public offering price of $10 per ADS.

Oppenheimer & Co. Inc. is acting as sole book-running manager of the offering. Ladenburg Thalmann & Co. Inc. is acting as lead manager of the offering.

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus) induced skin and soft tissue infections.

You May Also Be Interested In

• Rubrik IPO: 5 key things to know
• Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
• Trident Digital Tech Holdings (TDTH) Announces Downsized 1.8M ADS IPO at $5-$7/sh